title: A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.
abstract: A new vaccine (the 4CMenB 4-component protein vaccine [Bexsero], which includes PorA, factor H-binding protein [fHbp], neisserial heparin-binding antigen [NHBA], and Neisseria adhesin A [NadA]) against serogroup B meningococci has recently been approved for use in people older than age 2 months in Europe, Australia, and Canada. Preapproval clinical efficacy studies are not feasible for invasive meningococcal disease because its incidence is low/very low, and the serum bactericidal antibody (SBA) titer (or the human SBA [hSBA] titer when human complement is used in the assay) has been used as a surrogate marker of protection. However, the hSBA assay cannot be used on a large scale, and therefore, a meningococcal antigen typing system (MATS) was developed. MATS combines conventional PorA genotyping with an enzyme-linked immunosorbent assay (ELISA) that quantifies both the expression and the cross-reactivity of antigenic variants. The assay has been used to evaluate the potential of the 4CMenB meningococcal group B vaccine to cover group B strains in several countries. Some recent data suggest that MATS is a conservative predictor of strain coverage. We used pooled sera from adolescents and infants to test by the hSBA assay 10 meningococcal group B strains isolated in Spain that were negative for the 3 antigens (n = 9) or that had very low levels of the 3 antigens (n = 1) by MATS. We found that all strains were killed by sera from adolescents and that 5 of the 10 strains were also killed, although at a low titer, by sera from infants. Our data confirm that MATS underestimates vaccine coverage.
authors: Reference Laboratory for Meningococci, Institute of Health Carlos III, Majadahonda, Spain rabad@isciii.es.
authors: R
authors: R
authors: Abad
authors: Novartis Vaccines, Siena, Italy.
authors: A
authors: A
authors: Biolchi
authors: Novartis Vaccines, Siena, Italy.
authors: M
authors: M
authors: Moschioni
authors: Novartis Vaccines, Siena, Italy.
authors: M M
authors: MM
authors: Giuliani
authors: Novartis Vaccines, Siena, Italy.
authors: M
authors: M
authors: Pizza
authors: Reference Laboratory for Meningococci, Institute of Health Carlos III, Majadahonda, Spain.
authors: J A
authors: JA
authors: Vázquez
mesh_terms: D000293:Adolescent; D000942:Antigens, Bacterial / Q000032:analysis / Q000235:genetics / Q000276:immunology; D015373:Bacterial Typing Techniques; D001770:Blood Bactericidal Activity; D004797:Enzyme-Linked Immunosorbent Assay; D005838:Genotype; D060005:Genotyping Techniques; D006801:Humans; D007223:Infant; D008589:Meningococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D050296:Microbial Viability; D009345:Neisseria meningitidis / Q000145:classification / Q000276:immunology* / Q000502:physiology; D010641:Phenotype; D018272:Porins / Q000032:analysis / Q000235:genetics / Q000276:immunology; D013030:Spain; D014611:Vaccination / Q000379:methods*
chemical_list: C570015:4CMenB vaccine; D000942:Antigens, Bacterial; D022401:Meningococcal Vaccines; D018272:Porins; C057699:porin protein, Neisseria
references: Vaccine. 2009 Jun 24;27 Suppl 2:B64-70
references: 19464092
references: Clin Vaccine Immunol. 2007 Dec;14(12):1596-602
references: 17913865
references: Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19490-5
references: 20962280
references: Vaccine. 2011 Feb 24;29(10):1968-73
references: 21241734
references: JAMA. 2012 Feb 8;307(6):573-82
references: 22318278
references: Lancet. 2012 Feb 18;379(9816):617-24
references: 22260988
references: Vaccine. 2012 May 30;30 Suppl 2:B73-7
references: 22607902
references: Clin Vaccine Immunol. 2012 Oct;19(10):1609-17
references: 22875603
references: Lancet Infect Dis. 2013 May;13(5):416-25
references: 23414709
references: Vaccine. 2013 Oct 9;31(43):4968-74
references: 23954380
references: Vaccine. 2013 Dec 17;32(1):124-30
references: 23588089
references: Drugs. 2014 Jan;74(1):15-30
references: 24338083
references: J Exp Med. 1969 Jun 1;129(6):1307-26
references: 4977280
references: Infect Immun. 1999 May;67(5):2441-51
references: 10225907
references: N Engl J Med. 2010 Apr 22;362(16):1511-20
references: 20410516